12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

IDegLira regulatory update

Novo Nordisk submitted an MAA to EMA for IDegLira to treat Type II diabetes. IDegLira is a fixed-dose combination of Novo's Victoza liraglutide and the company's...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >